Exclusive Report Series

Overpatented, Overpriced

How excessive pharmaceutical patenting
is extending monopolies and driving up drug prices.
Featured in the New York Times and NBC News

 

Revealed: How patent abuse in the U.S. is impacting the 10 top selling drugs.

Read the Report
Access Detailed Information on

America's Top-Selling Drugs

Read our investigations about everyday drugs that are overpatented and overpriced. Click each one to read more:

The Burden
of Patent
Thickets
Extending patent protection nets drugmakers $158 billion on just four drugs
Read the Report
Imbruvica
Over half of its patents are for indications, not the drug itself

Data from 2020
Read the Report
Keytruda
50% of the patent applications were filed after its first FDA approval

Data from 2021
Read the Report
Humira
Largest number of patent applications in the top 12

Data from 2018
Read the Report
Lantus
95% of its patent applications were filed after it was on the market

Data from 2018
Read the Report
Enbrel
One of the largest price hikes in the last 6 years

Data from 2018
Read the Report
Overpatented, Overpriced
How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices

Data from 2018
Read the Report

Learn more about how you can help build a more equitable system for all